156 related articles for article (PubMed ID: 37306711)
1. Outcome and risk prediction of early progression in patients with extranodal natural killer/T cell lymphoma from the CLCG study.
Li JY; Hou XR; Chen SY; Liu X; Zhong QZ; Qian LT; Qiao XY; Wang H; Zhu Y; Cao JZ; Wu JX; Wu T; Zhu SY; Shi M; Zhang HL; Zhang XM; Su H; Song YQ; Zhu J; Zhang YJ; Huang HQ; Wang Y; He X; Zhang LL; Qu BL; Yang Y; Hu C; Deng M; Wang SL; Qi SN; Li YX
Ann Hematol; 2023 Sep; 102(9):2459-2469. PubMed ID: 37306711
[TBL] [Abstract][Full Text] [Related]
2. Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study.
Yang Y; Wang Y; Liu X; He X; Zhang LL; Wu G; Qu BL; Qian LT; Hou XR; Zhang FQ; Qiao XY; Wang H; Li GF; Zhu Y; Cao JZ; Wu JX; Wu T; Zhu SY; Shi M; Xu LM; Su H; Song YQ; Zhu J; Zhang YJ; Huang HQ; Hu C; Qi SN; Li YX
Leukemia; 2021 Jun; 35(6):1671-1682. PubMed ID: 32943751
[TBL] [Abstract][Full Text] [Related]
3. Primary site and regional lymph node involvement are independent prognostic factors for early-stage extranodal nasal-type natural killer/T cell lymphoma.
Niu SQ; Yang Y; Li YY; Wen G; Wang L; Li ZM; Wang HY; Zhang LL; Xia YF; Zhang YJ
Chin J Cancer; 2016 Apr; 35():34. PubMed ID: 27044275
[TBL] [Abstract][Full Text] [Related]
4. Nomograms based on SUVmax of
Li H; Shao G; Zhang Y; Chen X; Du C; Wang K; Gao Z
Cancer Imaging; 2021 Jan; 21(1):9. PubMed ID: 33419476
[TBL] [Abstract][Full Text] [Related]
5. Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials.
Maurer MJ; Habermann TM; Shi Q; Schmitz N; Cunningham D; Pfreundschuh M; Seymour JF; Jaeger U; Haioun C; Tilly H; Ghesquieres H; Merli F; Ziepert M; Herbrecht R; Flament J; Fu T; Flowers CR; Coiffier B
Ann Oncol; 2018 Aug; 29(8):1822-1827. PubMed ID: 29897404
[TBL] [Abstract][Full Text] [Related]
6. Circulating Low Absolute CD4+ T Cell Counts May Predict Poor Prognosis in Extranodal NK/T-Cell Lymphoma Patients Treating with Pegaspargase-Based Chemotherapy.
Zhang YP; Zhang R; Zhu HY; Wang L; Wu YJ; Liang JH; Shi WY; Liu H; Xu W; Li JY
Cancer Res Treat; 2019 Jan; 51(1):368-377. PubMed ID: 29764116
[TBL] [Abstract][Full Text] [Related]
7. [Clinical features and treatment outcome of extranodal nasal-type NK/T-cell lymphoma of the extra-upper aerodigestive tract].
Zhao YT; Wang Y; Qi SN; Yang Y; He X; Zhang YJ; Huang HQ; Zhang LL; Wu G; Qu BL; Qian LT; Hou XR; Zhang FQ; Qiao XY; Wang H; Li GF; Zhu Y; Cao JZ; Wu JX; Wu T; Zhu SY; Shi M; Xu LM; Yuan ZY; Su H; Song YQ; Zhu J; Li YX
Zhonghua Zhong Liu Za Zhi; 2021 Jul; 43(7):787-794. PubMed ID: 34289574
[No Abstract] [Full Text] [Related]
8. A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis.
Kim SJ; Yoon DH; Jaccard A; Chng WJ; Lim ST; Hong H; Park Y; Chang KM; Maeda Y; Ishida F; Shin DY; Kim JS; Jeong SH; Yang DH; Jo JC; Lee GW; Choi CW; Lee WS; Chen TY; Kim K; Jung SH; Murayama T; Oki Y; Advani R; d'Amore F; Schmitz N; Suh C; Suzuki R; Kwong YL; Lin TY; Kim WS
Lancet Oncol; 2016 Mar; 17(3):389-400. PubMed ID: 26873565
[TBL] [Abstract][Full Text] [Related]
9. When do we need central nervous system prophylaxis in patients with extranodal NK/T-cell lymphoma, nasal type?
Kim SJ; Oh SY; Hong JY; Chang MH; Lee DH; Huh J; Ko YH; Ahn YC; Kim HJ; Suh C; Kim K; Kim WS
Ann Oncol; 2010 May; 21(5):1058-63. PubMed ID: 19850636
[TBL] [Abstract][Full Text] [Related]
10. [Long-term effect of risk-adaptive therapy for early stage extranodal NK/T cell lymphoma].
Wu T; Liu QL; Hu YF; Zhang J; Chen MX; Chen XX; Huang YH; Lu B
Zhonghua Zhong Liu Za Zhi; 2019 Nov; 41(11):859-864. PubMed ID: 31770855
[No Abstract] [Full Text] [Related]
11. Prognostic factors and treatment outcomes for patients with stage II extranodal nasal-type natural killer/T-cell lymphoma of the upper aerodigestive tract.
Fang H; Jin J; Wang WH; Wang SL; Zhou LQ; Li YX
Leuk Lymphoma; 2014 Aug; 55(8):1832-7. PubMed ID: 24144309
[TBL] [Abstract][Full Text] [Related]
12. Characteristics, Prognostic Factors, and Survival of Patients with NK/T-Cell Lymphoma of Non-upper Aerodigestive Tract: A 17-Year Single-Center Experience.
Liu ZL; Bi XW; Zhang XW; Lei DX; Liu PP; Yang H; Gao Y; Jiang YX; Jiang WQ; Xia Y
Cancer Res Treat; 2019 Oct; 51(4):1557-1567. PubMed ID: 30971067
[TBL] [Abstract][Full Text] [Related]
13. Progression-free survival at 24 months as a predictor of survival outcomes after CHOP treatment in patients with peripheral T-cell lymphoma: a single-center validation study in a Japanese population.
Shirouchi Y; Yokoyama M; Fukuta T; Uryu H; Nishimura N; Mishima Y; Inoue N; Tsuyama N; Takeuchi K; Terui Y
Leuk Lymphoma; 2021 Aug; 62(8):1869-1876. PubMed ID: 33688781
[TBL] [Abstract][Full Text] [Related]
14. Progression-Free Survival at 24 Months as A Landmark After Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B-cell Lymphoma.
Tun AM; Maliske S; Wang Y; Inwards DJ; Habermann TM; Micallef I; Porrata L; Paludo J; Bisneto JV; Rosenthal A; Kharfan-Dabaja MA; Ansell SM; Nowakowski GS; Farooq U; Johnston PB
Transplant Cell Ther; 2022 Sep; 28(9):610-617. PubMed ID: 35752441
[TBL] [Abstract][Full Text] [Related]
15. Increased body mass index is associated with improved overall survival in extranodal natural killer/T-cell lymphoma, nasal type.
Li YJ; Yi PY; Li JW; Liu XL; Liu XY; Zhou F; OuYang Z; Sun ZY; Huang LJ; He JQ; Yao Y; Fan Z; Tang T; Jiang WQ
Oncotarget; 2017 Jan; 8(3):4245-4256. PubMed ID: 28002803
[TBL] [Abstract][Full Text] [Related]
16. Real-World clinical features and survival outcomes associated with primary gastrointestinal natural killer/T-cell lymphoma from 1999 to 2020.
Chunli Y; Ming J; Ziyan M; Jie J; Shuli L; Jie H; Yu W; Caigang X; Liqun Z
Cancer Med; 2023 Feb; 12(3):2614-2623. PubMed ID: 36114786
[TBL] [Abstract][Full Text] [Related]
17. Evidence of cure for extranodal nasal-type natural killer/T-cell lymphoma with current treatment: an analysis of the CLCG database.
Liu X; Zhang LL; Qu BL; Zhong QZ; Qian LT; Yang Y; Hou XR; Qiao XY; Wang H; Zhu Y; Cao JZ; Wu JX; Wu T; Zhu SY; Shi M; Zhang HL; Zhang XM; Su H; Song YQ; Zhu J; Zhang YJ; Huang HQ; Wang Y; Chen F; Yin L; He X; Cai S; Li YX; Qi SN
Haematologica; 2023 Sep; 108(9):2467-2475. PubMed ID: 36951150
[TBL] [Abstract][Full Text] [Related]
18. A New Prognostic Index for Extranodal Natural Killer/T-Cell Lymphoma:Incorporation of Serum β-2 Microglobulin to PINK.
Kang S; Cho H; Kim S; Lee K; Kang EH; Park JS; Lee YS; Park CS; Go H; Huh J; Ryu JS; Lee SW; Kim SJ; Kim WS; Yoon SE; Ko YH; Suh C
Cancer Res Treat; 2023 Jan; 55(1):314-324. PubMed ID: 35381163
[TBL] [Abstract][Full Text] [Related]
19. CD56-negative extranodal NK/T cell lymphoma should be regarded as a distinct subtype with poor prognosis.
Wang L; Wang Z; Xia ZJ; Lu Y; Huang HQ; Zhang YJ
Tumour Biol; 2015 Sep; 36(10):7717-23. PubMed ID: 25935537
[TBL] [Abstract][Full Text] [Related]
20. A modified international prognostic index including pretreatment hemoglobin level for early stage extranodal natural killer/T cell lymphoma.
Wang L; Xia ZJ; Lu Y; Wang QX; Niu SQ; Huang HQ; Zhang YJ
Leuk Lymphoma; 2015; 56(11):3038-44. PubMed ID: 25747971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
